UTHR: Pulmonary fibrosis breakthroughs and a robust pipeline drive a projected 10x revenue surge
A major clinical and commercial transformation is underway, with best-in-class pulmonary fibrosis data, a rapidly expanding pipeline, and a projected 10x increase in addressable market and revenue. Fourteen launches are planned by 2029, and a $500M buyback was announced.Based on United Therapeutics…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.